You’ve reached the visitor articles limitFree registration reserved for healthcare professionals
FDA approved Endari (L-glutamine) for the treatment of sickle cell disease to reduce severe complications associated with the blood disorder in patients aged = 5 years.
Sickle cell disease is an inherited blood disorder characterised by abnormal red blood cells. This may restrict the blood flow and oxygen supply to the body’s tissues which may cause severe pain and organ damage. As per National Institutes of Health, around 100,000 people in US have sickle cell disease. This disease is more common in African-Americans, Latinos, and other minority groups. The average life expectancy for patients with sickle cell disease in US is 40-60 years.
The safety and efficacy of Endari were established in randomized trial of patients aged 5-58 years old with sickle cell disease who experienced two or more painful crises within the 12 months. Patients were randomly assigned to receive treatment with...